Introduction {#s1}
============

CHARGE syndrome is an autosomal dominant genetic disorder characterized by [c]{.ul}oloboma of iridis, [h]{.ul}eart defect, [a]{.ul}tresia choanae, [r]{.ul}etarded growth, [g]{.ul}enital hypoplasia, and [e]{.ul}ar anomalies, a constellation of non-randomly associated malformations ([@bib10]). This syndrome is relatively common, occurring approximately one in 10,000 births. Since the first report that de novo mutations in *CHD7* (chromodomain helicase DNA binding protein 7) might be the cause of CHARGE syndrome ([@bib57]), several groups have sought to identify genotype-phenotype correlations and to determine how various phenotypic features of CHARGE are contributed to by *CHD7* mutations ([@bib3]; [@bib48]; [@bib60]).

CHD7 is expressed in various cell types, including pluripotent stem cells and cells of the neural tube and placodal regions ([@bib2]). CHD7 modulates chromatin formation by binding to genomic DNA and regulating the expression of downstream genes ([@bib33]). For instance, several transcriptional factors, such as SOX2, SOX9, and SOX10, have been reported to cooperate with CHD7 in regulating early development in various cell types ([@bib6]) ([@bib19]) ([@bib23]) ([@bib35]) ([@bib49]).

The hypothesis that clinical features observed in CHARGE syndrome patients are caused by abnormalities in neural crest development has been proposed for more than 30 years ([@bib50]). The cells of the neural crest contribute to many different tissue lineages, including those of the craniofacial skeleton, cranial nerves (VII, VIII, IX and X), ears, eyes, and heart. Since many of the defects observed in CHARGE syndrome appear to be related to abnormalities of cranial neural crest cells, this syndrome is considered as a 'neurocristopathy' ([@bib2]; [@bib48]; [@bib50]). A recent study supports this view by showing that the knockdown of CHD7 in human embryonic stem cells (hESCs) results in migratory neural crest formation defects ([@bib6]). Moreover, the knockdown of *Chd7* in *Xenopus laevis* or zebrafish embryos led to abnormalities in neural crest specification and migration ([@bib5]) ([@bib6]). The hypothesis that the neural crest pathophysiology observed in CHARGE syndrome is attributable to NCC defects has not been examined using patient-derived cells due to technical challenges. In addition, the phenotypic aspects of CHARGE patient-derived NCCs with respect to different migratory behaviors have not been examined in detail.

Thus, there is great potential value in the establishment of in vitro models of this syndrome using patient-derived cells for use in the study of CHARGE pathophysiology. In the present study, we generated NCCs from CHARGE syndrome patient-derived iPSCs, established in vitro models of CHARGE syndrome, and observed defective migration in CHARGE NCCs via in vitro and in vivo experiments.

Results {#s2}
=======

Clinical features of enrolled CHARGE patients and generation of patient-derived iPSCs {#s2-1}
-------------------------------------------------------------------------------------

To gain mechanistic insights into the pathogenesis of CHARGE syndrome, we enrolled two CHARGE patients, designated patient 1 (CH1) and patient 2 (CH2), in the present study in an effort to generate patient-derived iPSCs. Both patients have a heterozygous nonsense mutation in *CHD7*, and exhibited the typical phenotype of CHARGE syndrome ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). We collected fibroblasts from these patients and generated 25 and 23 iPSC clones from CH1 and CH2, respectively, following the four-factor protocol first reported by Takahashi and Yamanaka ([@bib54]). We selected four lines from CH1 (CH1\#7, CH1\#11, CH1\#20, CH1\#25) and three lines from CH2 (CH2\#1, CH2\#16, CH2\#19) for further analyses. As shown in [Figure 1A--C](#fig1){ref-type="fig"}, these iPSC clones showed characteristics of pluripotent stem cells, including a morphology similar to that of human embryonic stem cells (ESCs) ([Figure 1A](#fig1){ref-type="fig"}), the expression of pluripotent stem cell markers (TRA1-60 and TRA1-81) ([Figure 1B](#fig1){ref-type="fig"}), and the capacity for teratoma formation ([Figure 1C](#fig1){ref-type="fig"}). We confirmed that the CH1-iPSCs and CH2-iPSCs retained the *CHD7* mutations observed in the human dermal fibroblasts (HDFs) of origin, whereas none of the control iPSCs harbored mutations in *CHD7* ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These patient-derived iPSCs enabled us to conduct further in vitro characterization of phenotypes relevant to CHARGE syndrome. Interestingly, the expression levels of *CHD7* mRNA in the iPSCs derived from both patients were significantly lower than those in control iPSCs ([Figure 1E](#fig1){ref-type="fig"}).

![Characterization of CHARGE patient-derived iPSCs.\
(**A**) Representative images of generated iPSCs from CHARGE patients CH1 and CH2 showing human ESC-like morphologies. Bar: 300 μm. (**B**) TRA1-60 and TRA1-81 protein, pluripotent markers, expression in CHARGE iPSCs. Bar: 300 μm. (**C**) Hematoxylin and eosin staining of teratoma derived from CHARGE iPSCs, which were transplanted into the testes of NOD-SCID mice. Bar: 300 μm. (**D**) Direct sequencing analysis of the *CHD7* mutations in CHARGE patient's fibroblasts and iPSCs. The original *CHD7* mutations in the patient's fibroblasts were conserved in the generated iPSCs. The corresponding sequences in control iPSCs are shown below. (**E**) qRT-PCR analysis showed that *CHD7* mRNA expression is significantly reduced in both sets of CHARGE-iPSCs. Control iPSCs (WD39, 201B7, and 1210B2); CH1, 21 lines (CH1\#1, \#3--17, \#19--21, \#24, \#25); CH2, 15 lines (CH2\#1--3, \#5, \#7--8, \#10, \#16--23). Technical replicates = 3, Biological replicates (the number of independent sample collection from cells per group) \>3, mean ± S.D., n.s.: not significant, \*p\<0.05, \*\*p\<0.01 (Dunn's multiple comparisons test: compared with WD39). The following file is avail able for [Figure 1](#fig1){ref-type="fig"},[Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.005Figure 1---source data 1.Features and phenotypes of the enrolled CHARGE patients, and raw data and statistical data of [Figure 1](#fig1){ref-type="fig"}.Tab1: Features and phenotypes of the enrolled CHARGE patients. Both patients showed symptoms typical of CHARGE syndrome. Tab2: Statistical data of [Figure 1F](#fig1){ref-type="fig"}. qRT-PCR analysis of *CHD7* using control and CHARGE iPSC lines.](elife-21114-fig1){#fig1}

Generation and characterization of control and CHARGE iPSC-NCCs {#s2-2}
---------------------------------------------------------------

Neural crest cells are thought to be the primary cells affected in CHARGE syndrome ([@bib10]) ([@bib48]). We therefore differentiated the patient-derived iPSCs into NCCs (iPSC-NCCs) using two protocols adapted from previous studies ([@bib6]) ([@bib29]), which we refer to as Methods A and B, respectively ([Figure 2A and D](#fig2){ref-type="fig"}). As shown in [Figure 2B and E](#fig2){ref-type="fig"}, control and CHARGE iPSC-NCCs obtained using each method displayed similar morphological features and were indistinguishable at the colony level. We initially examined the expression of neural crest markers, including CD271 (NGFR) and CD57 (B3GAT1) ([@bib56]), by flow cytometric analysis. As shown in [Figure 2C and F](#fig2){ref-type="fig"}, more than 90% of the cells obtained using these two methods from control and CHARGE iPSCs expressed both CD271 and CD57. The ratio of CD271 (+) CD57 (+) cells per total induced cells from CHARGE iPSCs was same as that of control without regard to the NCC differentiation method. We additionally performed an immuno-cytochemical analysis using additional NCCs markers, including SOX10 and AP2a, and we found that the iPSC-NCCs expressed these neural crest markers similarly ([Figure 2G](#fig2){ref-type="fig"}). These results indicate that iPSCs can be differentiated into NCCs, and that the NCC differentiation efficacy of CHARGE iPSCs was similar to that of control iPSCs.

![Differentiation of patient iPSCs into NCCs.\
The iPSC-NCCs in (**B**) and (**C**) were obtained by Method A, and the iPSC-NCCs in (**D**)-(**K**) were obtained by Method B. (**A**) Schematic presentation of the protocol for NCC differentiation from iPSCs using dual SMAD inhibition (Method A). (**B**) Representative phase-contrast images of control and CHARGE iPSC-NCCs. Bar: 500 μm. (**C**) (Left) Quantification of the ratio of the cell number of CD271 and CD57 double-positive cells per total induced cells calculated by flow cytometry. n.s., not significant (Unpaired t test, p=0.77). Biological replicates (independent inductions): Control, N = 3; CHARGE, N = 3. (Right) Representative flow cytometric CD271 and CD57 profiles of control and CHARGE iPSC-NCCs. (**D**) Schematic presentation of the protocol for NCC differentiation from iPSCs through neuroepithelial spheres (Method B). (**E**) Representative phase-contrast images of control and CHARGE iPSC-NCCs. Bar: 500 μm. (**F**) (Left) Quantification of the ratio of the cell number of CD271 and CD57 double-positive cells per total induced cells calculated by flow cytometry. n.s., not significant (Unpaired t test, p=0.55). Biological replicates (independent inductions): Control, N = 6; CHARGE, N = 4. (Right) Representative flow cytometric CD271 and CD57 profiles of control and CHARGE iPSC-NCCs. (**G**) Expression of SOX10 and AP2a protein in control and CHARGE iPSC-NCCs. Bar: 50 μm. (**H**) Expression of OTX2 in control and CHARGE iPSC-NCCs. Bar: 50 μm. (**I**) Representative images of CHARGE iPSC-NCCs differentiated into adipocytes, chondrocytes, and osteocytes in vitro. Bars: adipocytes: 50 μm, chondrocytes: 1000 μm, osteocytes: 500 μm. (**J**) Representative images of CHARGE iPSC-NCCs differentiated into myofibroblasts and peripheral neurons in vitro. Bars: 50 μm. (**K**) Representative images of control and CHARGE iPSC-NCCs differentiated into chondrocytes by transplantation into the testes of NOD-SCID mice. Bars: 300 μm. The following file is available for [Figure 2C and F](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.007Figure 2---source data 1.Raw data and statistical data of [Figure 2](#fig2){ref-type="fig"}.Tab1: Raw data and statistical data of [Figure 2C](#fig2){ref-type="fig"}. Flow-cytometric analysis using methodA iPSC-NCCs. Tab2: Raw data and statistical data of [Figure 2F](#fig2){ref-type="fig"}. Flow-cytometric analysis using methodB iPSC-NCCs.](elife-21114-fig2){#fig2}

The phenotypes of CHARGE syndrome show clear associations with defects in cranial NCCs ([@bib50]) ([@bib9]), which prompted us to investigate the expression of OTX2, a cranial marker ([@bib36]), by immunocytochemistry. We determined that OTX2 was expressed in both control and CHARGE iPSC-NCCs ([Figure 2H](#fig2){ref-type="fig"}). Moreover, using *ad hoc* protocols, we were able to differentiate CHARGE iPSC-NCCs into adipocytes, chondrocytes, osteocytes, myofibroblasts, and peripheral neurons ([Figure 2I, J and K](#fig2){ref-type="fig"}), indicating that these cells exhibit a potential for differentiation similar to control iPSC-NCCs ([@bib6]) ([@bib30]). This suggests that mutations in *CHD7* do not affect NCC differentiation per se. These results also indicate that iPSCs from CHARGE patients can be efficiently differentiated into NCCs that express precise positional markers of cranial region and retain the ability to differentiate into cranial neural crest cells, potentially enabling the generation of disease-relevant cellular models of neurocristopathies, such as CHARGE syndrome.

Transcriptomic differences between control iPSC-NCCs and CHARGE iPSC-NCCs suggest abnormal migration of CHARGE iPSC-NCCs {#s2-3}
------------------------------------------------------------------------------------------------------------------------

To identify the cellular functions dysregulated in CHARGE iPSC-NCCs, we performed a global gene expression analysis of NCCs derived from control and CHARGE iPSCs using a microarray. As shown in [Figure 3A](#fig3){ref-type="fig"}, we found that control and CHARGE iPSC-NCCs expressed essentially similar profiles of marker gene sets for early (*NGFR, B3GAT1, ITGA4*), premigratory (*PAX3, ZIC1*), and migratory (*TWIST1*) NCCs, suggesting the acquisition of the fundamental NCC gene expression profile in CHARGE iPSC-NCCs. The detection of *TWIST1* expression is notable, as one previous study reported that this gene, a marker of migratory NCCs, was downregulated in *CHD7* shRNA-infected human ESC-NCCs compared with control shRNA-infected cells ([@bib6]).

![Comparative gene expression analysis suggests migration defects in CHARGE iPSC-NCCs.\
(**A**) Scatter plot of control vs. CHARGE iPSC-NCCs obtained by Method B. Control: 201B7 iPSC-NCCs; CHARGE: CH2\#16 iPSC-NCCs. (**B**) Hierarchical clustering of 338 differentially expressed genes (FC \>1.25) between control and CHARGE iPSC-NCCs. The control lines consisted of 201B7 and WD39 iPSC-NCCs. The CHARGE lines consisted of CH1\#25 (CH1) and CH2\#16 (CH2). Each sample from the same line was prepared by independent NCC induction. (**C**) The top 20 list of the GO analysis of the 338 differentially expressed genes between control and CHARGE iPSC-NCCs. (**D**) Hierarchical clustering with 35 genes related to the GO term 'adhesion.' (**E**) Hierarchical clustering with 30 genes related to the GO term 'migration.' The following file is available for [Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---figure supplement 1---source data 1](#fig3s1sdata1){ref-type="supplementary-material"}.](elife-21114-fig3){#fig3}

We next extracted 338 differentially expressed genes (DEGs) (238 upregulated and 100 downregulated in CHARGE iPSC-NCCs) between control and CHARGE iPSC-NCCs (fold change \[FC\]\>1.25) in an effort to identify features common to genes with altered expression in CHARGE iPSC-NCCs ([Figure 3B](#fig3){ref-type="fig"}). A Gene Ontology (GO) analysis of this set showed enrichment for genes involved in vasculature development (p=2.08E-11), blood vessel development (p=1.24E-11), and blood vessel morphogenesis (p=1.23E-09). Interestingly, GO terms associated with 'cell migration' and 'cell motion' were also significantly enriched in these genes ([Figure 3C](#fig3){ref-type="fig"}). Given that NCC dysfunction is thought to be linked to the pathogenesis of CHARGE syndrome, we sought to examine the expression of genes associated with NCC behavior, specifically those related to cell migration and cell adhesion. We selected a set of genes listed under each GO term and compared their expression levels in control and CHARGE iPSC-NCCs. As shown in [Figures 3D, E](#fig3){ref-type="fig"} 56 genes under the GO terms 'migration' or 'adhesion' were differentially expressed. Quantitative real-time PCR (qRT-PCR) analyses performed for four selected genes, *POU3F2*, *OLFM3*, *CTGF* and *EDN1,* confirmed that the changes observed in the microarray data set were indeed significant, thereby providing a validation of the analysis ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These genes are also listed as CHD7 targets in the dataset. We also performed chromatin immunoprecipitation (ChIP)-qPCR for CHD7 using promoter primers for the genes to reveal direct CHD7 binding to these genes, and we found the direct binding of CHD7 to the distal promoter region in *EDN1* ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). The results of these transcriptome analyses support the notion that NCCs exhibit migratory and/or cell adhesion defects during embryonic development in CHARGE patients.

In the early stages of cranial neural crest cell migration, epithelial-to-mesenchymal transition (EMT) is thought to occur immediately prior to the delamination of NCCs from the neural crest. Migratory NCCs then begin their directed migration along the dorsolateral pathway, reaching their target and initiating their differentiation toward mature cell types ([@bib26]). Since CHARGE iPSC-NCCs showed only minimal defects in the initiation of NCC differentiation and subsequent differentiation into NCC derivatives, we hypothesized that sequential developmental processes, including delamination and migration, might be disrupted in CHARGE syndrome, as suggested by the results of our transcriptome analysis. We therefore next focused on the dysregulation of CHARGE iPSC-NCCs in cellular adhesion, migration, and cellular motion.

Defective scattering of CHARGE iPSC-NCCs {#s2-4}
----------------------------------------

The first step of the developmental journey of NCCs consists in their delamination from the region between the dorsal neural tube and the overlying ectoderm ([@bib26]). We first examined how control iPSC-NCCs migrated outward from spheres using iPSC-NCCs differentiated by Method A to model this particular event. As shown in [Figure 4---video 1](#fig4video1){ref-type="video"}, the cells began to spread out as a continuous monolayer (Phase 1) once the sphere became attached to the culture dish. The control iPSC-NCCs residing at the outermost periphery then began to scatter apart (Phase 2) ([Figure 4A--a](#fig4){ref-type="fig"}). In contrast, CHARGE iPSC-NCCs exhibited a distinct behavior in Phase 2, remaining closely associated with their neighbors ([Figure 4A--b](#fig4){ref-type="fig"}). To clarify this difference, we performed a time-lapse analysis of the initial phase of cell dispersion from the sphere. We used a method to calculate cell dispersion by a Delaunay triangulation algorithm (see Materials and methods) ([Figure 4B](#fig4){ref-type="fig"}). The distribution of the formed triangular area by the algorithm at 8 hr after the sphere attached to the plate was significantly increased relative to that at t = 0 for both control and CHARGE iPSC-NCCs ([Figure 4C](#fig4){ref-type="fig"}). Next, we analyzed differences in the increased cell dispersion (from t = 0 to t = 8 hr) between control and CHARGE cells by calculating the median size of the triangular area. We revealed a delayed dispersion of cells from CHARGE spheres ([Figure 4D](#fig4){ref-type="fig"}). Moreover, to determine whether CHARGE iPSC-NCCs have defects in premigratory-to-migratory transition, we analyzed the intercellular contacts of both control and CHARGE iPSC-NCCs at Phase 2. We visualized the cell associations by F-actin and nuclear staining ([Figure 4E](#fig4){ref-type="fig"}). Quantitative analysis of the number of intercellular contacts among the outermost migrating cells revealed significantly persistent intercellular contacts in CHARGE iPSC-NCCs in vitro ([Figure 4F](#fig4){ref-type="fig"}). CHARGE NCCs were reluctant to disperse as single cells, in contrast with control NCCs. This suggests that NCC delamination from the neural tube may be affected in CHARGE syndrome.

![Defective Scattering of CHARGE iPSC-NCCs in vitro.\
(**A**) Representative images of control and CHARGE iPSC-NCCs obtained by Method A. The control iPSC-NCCs residing at the outermost periphery began to scatter apart ([Figure 4A--a](#fig4){ref-type="fig"}). In contrast, the CHARGE iPSC-NCCs exhibited a distinct behavior in Phase 2, remaining closely associated with their neighbors ([Figure 4A--b](#fig4){ref-type="fig"}). The red square on the left corresponds to that on the right in both a and b. Bars (left in a and b): 250 μm. Bars (right in a and b): 100 μm. (**B**) Cell dispersion at t = 0, and t = 8 hr was analyzed using the Delaunay triangulation algorithm. Control: WD39; CHARGE: CH1\#25. Bar:100 μm. (**C**) Dot plots represent the distribution of each triangular area shown in (**B**). (Left) Triangular area of the control iPSC-NCCs at t = 0 and t = 8 hr. \*\*p\<0.01 (Mann-Whitney U test, Cohen's d 0.39). (Right) Triangular area of the CHARGE iPSC-NCCs at t = 0 and t = 8 hr. \*\*p\<0.01 (Mann-Whitney U test, Cohen's d 0.03). (**D**) Blue bars represent for control iPSC-NCCs, and red bars represent for CHARGE iPSC-NCCs. (Left) Median of the triangular area of the control and CHARGE iPSC-NCCs at t = 0 and t = 8 hr. Control iPSC-NCCs, N = 8 (WD39, 201B7, 1201C1); CHARGE iPSC-NCCs, N = 15 (CH1\#20, CH1\#25, CH2\#1). (Right) Box plots showing the increased median value of the triangular area from t = 0 to t = 8 hr. \*\*p\<0.01 (Mann-Whitney U test, Cohen's d 1.66). (**E**) Representative images of iPSCs-NCCs at the outermost periphery visualized with F-actin and nuclear staining. Bar: 100 μm. Gray quarter circles show the postion of each sphere. (**F**) The outermost nine cells (green circle) in each of the eight 45 degree-sector of a sphere were scored by counting the number of their contacting-neighboring cells. The number in a green circle represents the score. The box plots show the distribution of the number of intercellular contacts among the outermost migrating cells in each line. Biological replicates: control, 15 inductions (KhES1, 3; WD39, 3; 201B7, 5; WA29, 4); CH1, 7 inductions (CH1\#20, 3; CH1\#25, 4); CH2, 12 inductions (CH2\#1, 4; CH2\#16, 3; CH2\#19, 5). Number of cells scored: control, 3707 cells (KhES1, 1017 cells; WD39, 1197 cells; 201B7, 657 cells; WA29, 836 cells); CH1, 3600 cells (CH1\#20, 1989 cells; CH1\#25, 1611 cells); CH2, 3213 cells (CH2\#1, 738 cells; CH2\#16, 1791 cells; CH2\#19, 684 cells). n = 0; \*\*p\<0.01 (Dunnett's multiple comparisons test; Cohen's d 2.67 (control vs CH1), Cohen's d 1.93 \[control vs CH2\]). n = 1; n.s.; not significant, \*\*p\<0.01 (Dunn's multiple comparisons test; Cohen's d (control vs CH1) 1.02, Cohen's d 1.71 \[control vs CH2\]. n \> 1; \*\*p\<0.01 (Dunnett's multiple comparisons test; Cohen's d 2.88 (control vs CH1), Cohen's d 1.54 \[control vs CH2\]). The following file is available for [Figure 4](#fig4){ref-type="fig"}, [Figure 4---video 1](#fig4video1){ref-type="video"} and [2](#fig4video2){ref-type="video"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.012Figure 4---source data 1.Raw data and statistical data of [Figure 4](#fig4){ref-type="fig"}.Tab 1: Statistical data of [Figure 4C](#fig4){ref-type="fig"}. a. Statistical data of [Figure 4C](#fig4){ref-type="fig"} (left). Control (WD39): t = 0 vs t = 8 hr. b. Statistical data of [Figure 4C](#fig4){ref-type="fig"} (right). CHARGE (CH1\#25): t = 0 vs t = 8 hr. c. Statistical data of [Figure 4C](#fig4){ref-type="fig"} (left and right). Tab 2: Statistical data of [Figure 4D](#fig4){ref-type="fig"}. Tab 3: Statistical data of [Figure 4F](#fig4){ref-type="fig"}. Tab 4: Raw data of [Figure 4F](#fig4){ref-type="fig"}. N: the number of neighbouring cells attached with the nine outermost cells in each of the eight 45 degree-sector of a sphere. White columns show the number of N = 0, 1, or \>1 cells per sphere.](elife-21114-fig4){#fig4}

Migratory disabilities in CHARGE iPSC-NCCs {#s2-5}
------------------------------------------

Following delamination from the neural tube, NCCs travel throughout the developing embryo and contribute to major NCC-derived organs ([@bib14]) ([@bib51]) ([@bib9]). To assess the migratory ability of CHARGE iPSC-NCCs, we assessed the trans-well migration of dissociated iPSC-NCCs using the xCELLigence system (Roche). Using this system, cells migrating from the upper to lower well through fibronectin-coated microelectrode sensors were monitored automatically ([Figure 5A](#fig5){ref-type="fig"}). As shown in [Figure 5B](#fig5){ref-type="fig"}, the migration index of CHARGE iPSC-NCCs became lower than that of control cells after approximately 8 hr of monitoring. At 20 hr, we observed a decrease of approximately 50% in the migration index of the CHARGE iPSC-NCCs compared with that of control cells ([Figure 5C](#fig5){ref-type="fig"}). To exclude the possibility that the reduction in the number of migrating CHARGE iPSC-NCCs was due to reduced proliferation, we treated control iPSC-NCCs with an antimitotic, aphidicolin. Aphidicolin treatment did not have a significant effect on the migration index of iPSC-NCCs ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Moreover, a BrdU incorporation assay indicated that the proliferative capacity of CHARGE iPSC-NCCs was not different from that of control iPSC-NCCs ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Additionally, to exclude the possibility that lower CHARGE iPSC-NCC adherence to fibronectin caused the reduction in the number of migrating CHARGE iPSC-NCCs in this assay, we performed a cell adhesion assay to fibronectin; we found no differential adherence to fibronectin between control and CHARGE iPSC-NCCs ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Taken together, these results suggest that CHARGE iPSC-NCCs exhibit aberrant migration, in contrast with their preserved capacity for proliferation and adherence to fibronectin.

![Migratory disabilities of CHARGE iPSC-NCCs.\
(**A**) xCELLigence. The migration index of iPSC-NCCs was measured using xCELLigence, by which migrating cells through microelectrode sensors were monitored automatically. (**B**) Representative curve of control (WD39; red) and CHARGE (CH2\#1; blue) iPSC-NCCs migration index during 36 hr. Bar: SD. (**C**) Quantitative analysis of migration index after 20 hr of monitoring with xCELLigence, normalized to the control iPSC-NCCs migration index. Bar: SD. Biological replicates (the number of independent NCC inductions): control, N = 20 (WD39, N = 8; 201B7, N = 7; 1210B2, N = 5); CH1, N = 6 (CH1\#7, N = 1, CH1\#20, N = 1; CH1\#25, N = 4); CH2, N = 11 (CH2\#1, N = 5; CH2\#16, N = 5; CH2\#19, N = 1). Technical replicates: 2--4 per experiment. \*\*p\<0.01 (Turkey's multiple comparisons test): The following file is available for [Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.017Figure 5---source data 1.Raw data of xCelligence assay of iPSC-NCCs in vitro.Tabs \'Experiment 1\' - \'Experiment 13\': Raw data of migration indexes in each experiment. Each table in a sheet shows an independent experiment. Orange column shows migration index at 20 hr, and is used for quantitative analysis in [Figure 5C](#fig5){ref-type="fig"}. Tab 1: Statistical data of [Figure 5C](#fig5){ref-type="fig"}. Quantitative analysis of migration index after 20 hr of monitoring with xCELLigence, normalized to the control iPSC-NCCs migration index. Tab 2: Raw data and statistical data of [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. Control iPSC-NCCs migration index upon treatment with aphidicolin or vehicle for 36 hr. Tab 3: Raw data and statistical data of [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}. BrdU assay of control and CHARGE iPSC-NCCs at 24 hr after replating. Tab 4: Raw data and statistical data of [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}. Cell adhesion assay of control and CHARGE iPSC-NCCs to fibronectin.](elife-21114-fig5){#fig5}

Defective spontaneous motility in CHARGE iPSC-NCCs in vitro {#s2-6}
-----------------------------------------------------------

The defective scattering and trans-well migration of CHARGE iPSC-NCCs suggest that the collective migration of NCCs is affected. We wondered whether this might be attributable, at least in part, to an intrinsic motility defect of individual CHARGE iPSC-NCCs. Therefore, we performed a time-lapse analysis to examine the single-cell spontaneous motility of control (201B7) and CHARGE (CH1\#25) iPSC-NCCs. To exclude cell-density effects, we analyzed the motility of mixed iPSC-NCCs, i.e., control + CHARGE, within the same well ([Figure 6A](#fig6){ref-type="fig"}). The tracking of individual iPSC-NCCs revealed that the average velocities progressively increased over the course of the recording period ([Figure 6B](#fig6){ref-type="fig"}). Notably, at any time interval, the average velocity of the CHARGE iPSC-NCCs was lower than that of control iPSC-NCCs (Sidak\'s multiple comparisons test after two-way repeated measures ANOVA: pTime \<0.001, pCellType \<0.001; 201B7, N = 80 cells tracked; CH1\#25, N = 97 cells tracked). Sidak's multiple comparisons tests confirmed the significantly reduced velocities of CHARGE iPSC-NCCs at multiple time intervals ([Figure 6B](#fig6){ref-type="fig"}). In contrast, the directionality of the iPSC-NCCs was constant over time and was similar for both control and CHARGE iPSC-NCCs ([Figure 6B](#fig6){ref-type="fig"}). A comparison of two different cell lines, WD39 and CH2\#16 ([Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}) yielded similar results; the average velocity of CHARGE iPSC-NCCs migrating as single cells was significantly reduced compared with that of control iPSC-NCCs (Sidak\'s multiple comparisons test after two-way repeated measures ANOVA: pTime \<0.001, pCellType \<0.001; WD39, N = 170 cells tracked; CH2\#16, N = 133 cells tracked). Sidak's multiple comparisons tests confirmed the significantly reduced velocities of CHARGE iPSC-NCCs at multiple time intervals. In contrast, the directionality of CHARGE iPSC-NCCs was not different to that of control iPSC-NCCs, indicating that the abnormal migration of CHARGE iPSC-NCCs is due, at least in part, to a defective intrinsic motility.

![Single cell motility analysis of iPSC-NCCs in vitro.\
(**A**) Representative images of migratory 201B7 (control; green) and CH1\#25 (CHARGE; red) iPSC-NCCs at 0 hr and 16 hr, along with a combined view. Bar: 50 μm. (**B**) Average velocities of migratory iPSC-NCCs were assessed by tracking control and CHARGE iPSC-NCCs for 16 hr. Number of cells tracked: 201B7, 89 cells tracked; CH1\#25, 124 cells tracked. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (Sidak's multiple comparisons tests). (**C**) Quantitative analysis of the directionality of migratory iPSC-NCCs tracked in (**B**). n.s., not significant (Tukey\'s multiple comparisons test). Bars in (**B**) and (**C**) display the mean ± SEM. The following file is available for [Figure 6](#fig6){ref-type="fig"}, [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Figure 6---figure supplement 1---source data 1](#fig6s1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.021Figure 6---source data 1.Raw data and statistical data of [Figure 6](#fig6){ref-type="fig"}Tab 1: Statistical data of [Figure 6B](#fig6){ref-type="fig"}. Average velocities of migratory iPSC-NCCs assessed by tracking control and CHARGE iPSC-NCCs for 16 hr. Tab 2: Raw data of single cell motility analysis of iPSCs-NCCs in vitro. Quantitative analysis in [Figure 6B](#fig6){ref-type="fig"} was calculated using the data below. Tab 3: Statistical data of [Figure 6C](#fig6){ref-type="fig"}. Tab 4: Raw data of single cell motility analysis of iPSCs-NCCs in vitro. Quantitative analysis in [Figure 6C](#fig6){ref-type="fig"} was calculated using the data below.](elife-21114-fig6){#fig6}

Defective migration of CHARGE iPSC-NCCs in chick embryos {#s2-7}
--------------------------------------------------------

To examine whether CHARGE iPSC-NCCs also show defective migration in vivo, we grafted iPSC-NCCs into the dorsal edge of the hindbrain of chick embryos (HH stage 8--10). To compare the migration ability of CHARGE iPSC-NCCs and control cells under identical conditions, we transplanted a mixture of control and CHARGE iPSC-NCCs into the same embryo. To distinguish these cells, the iPSC-NCCs were stained with different lipophilic dyes (Vybrant DiI or DiO) before transplantation ([Figure 7A](#fig7){ref-type="fig"}). First, to examine the serial migration of the transplanted cells, we transferred the transplanted embryo to a glass-bottomed plate (IWAKI) 6 hr after transplantation and then acquired time-lapse images every 20 min ([Figure 7--video 1](#fig7video1){ref-type="video"}). We tracked 4--14 cells migrating well for both control and CHARGE cells in an embryo (the average \# of counted cells per experiment: control, 8.9; CHARGE, 9.0), and we calculated their velocity at each time interval using ImageJ ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). In 6 of 9 transplanted embryos, the velocity of CHARGE iPSC-NCCs was significantly less than that of control cells. In the other 3 embryos, there were no differences between control and CHARGE cells. ([Figure 7---figure supplement 1---source data 1](#fig7s1){ref-type="fig"} -tab1) Collectively, CHARGE iPSC-NCCs exhibited a lower velocity compared with that of the co-transplanted control iPSC-NCCs (p=0.03; Wilcoxon signed-rank test) ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Second, we examined the iPSC-NCCs that had migrated throughout the embryo *in ovo* thirty-six hours after transplantation. Interestingly, the iPSC-NCCs migrated from the site of transplantation (dorsal area) to the ventral area ([Figure 7B](#fig7){ref-type="fig"}, lower panels). Both control and CHARGE iPSC-NCCs migrated in the expected direction, consistent with the normal developmental routes of NCCs. Notably, CHARGE iPSC-NCCs did not follow abnormal routes to ectopic sites in this model. To compare the migration of control and CHARGE iPSC- NCCs in vivo, we scored the maximum distance that the transplanted cells migrated in 17 surviving chick embryos ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). We recorded the locations of the iPSC-NCCs-derived cells that had migrated the greatest distance from the transplant site and assigned a score from 1 (dorsal area) to 4 (ventral area) to each grafted embryo ([Figure 7B](#fig7){ref-type="fig"}). As shown in [Figure 7C](#fig7){ref-type="fig"}, CHARGE iPSC-NCCs exhibited similar or lower migration scores compared with those of the co-transplanted control iPSC-NCCs. Adversely, the migration exhibited a large degree of variability among the embryos. These data suggest that the reduced migratory capability of CHARGE iPSC-NCCs observed in vitro reflects their reduced migration in vivo after transplantation in chick embryo.

![Defective migration of CHARGE iPSC-NCCs in chick embryos.\
(**A**) (Left) Representative image of in vitro control and CHARGE iPSC-NCCs that were prestained with Vybrant DiI and DiO, respectively. (Right) Representative image of chick embryo at the HH 8--10 stage in which iPSC-NCCs were injected around the hindbrain. (**B**) (Upper) Scoring of migration in transplanted chick embryos: Score I, dorsal side of otic cyst; Score II, around otic cyst; Score III, from ventral side of otic cyst to dorsal side of pharyngeal arch; Score IV, migrated into pharyngeal arches. (Lower-left panel) Example of chick embryos with a score of II. (Lower-right panel) Example of chick embryos with a score of IV. The asterisks in the panels of B indicate the NCC transplantation sites. (**C**) Graph of transplanted chick embryo scores; cells transplanted into the same embryo were connected with a line. \*\*p\<0.01 (Wilcoxon signed-rank test). The following file is available for [Figure 7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, [Figure 7---video 1](#fig7video1){ref-type="video"} and [Figure 7---figure supplement 1---source data 1](#fig7s1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.21114.025Figure 7---source data 1.A list of transplanted cells and scores.Tab 1: A list of transplanted cells and scores. Detais of the graph in [Figure 7C](#fig7){ref-type="fig"}. Transplanted control and CHARGE cells were stained with Vybrant DiI or DiO. We transplanted iPSC-NCCs into 93 embryos (HH8-10) in total, and 17 surviving embryoswere analyzed in this assay. Comparison of the maximum distance of Ctrl and CH shows that control cells migrated a greater distance from the site of transplant in some embryos evenly scored.](elife-21114-fig7){#fig7}

Our results show that NCCs differentiated from CHARGE iPSCs exhibit migration defects in vitro and in vivo that are consistent with the pathological features of CHARGE syndrome and thus may serve as a useful model for investigating the molecular causes of this condition.

Discussion {#s3}
==========

We successfully generated iPSCs from CHARGE syndrome patient-derived fibroblasts and differentiated them into NCCs. We identified multiple functional abnormalities in CHARGE iPSC-NCCs, which may reflect a direct link between the NCC population affected in CHARGE syndrome and the multiple anomalies observed in CHARGE syndrome patients ([Figure 8](#fig8){ref-type="fig"}). It was previously shown by *CHD7* knockdown in human ESCs that CHD7 controls EMT in multipotent NCCs ([@bib6]). Our results using CHARGE syndrome patient-derived iPSCs indicate that CHARGE iPSC-NCCs have migratory defects and that a series of migration-related behaviors following EMT, namely, delamination, migration, and motility, are affected.

![Model summarizing defective migration of CHARGE NCCs using patient-derived iPSCs.\
Defects in cell delamination, migration, and motility in our model reflect phenotypes in CHARGE syndrome that develop *in utero*. Various aspects of NCC migration were not well coordinated in CHARGE NCCs due to the dysfunction of CHD7.](elife-21114-fig8){#fig8}

First, our scattering assay using migratory iPSC-NCCs, which is an in vitro model of the premigratory-to-migratory transition, akin to delamination in vivo, indicated defective delamination in CHARGE NCCs ([Figure 4](#fig4){ref-type="fig"}). In this assay, iPSCs were induced into neuroectodermal spheres ([@bib28]), and the cells migrated out from the spheres. This migration of iPSC-NCCs out from neuroectodermal spheres resembles the premigratory-to-migratory transition, after which the migrating cells scattered as single cells in a manner similar to delamination in vivo. Our finding of defective CHARGE iPSC-NCCs scattering is compatible with a previous report that CHD7 controls the transcriptional reprogramming of EMT. As shown in [Figure 3E](#fig3){ref-type="fig"}, *FOXD1* expression was upregulated in CHARGE iPSC-NCCs. Since *FOXD1* is known to be expressed in premigratory NCCs and extinguished once migration occurs ([@bib18]), altered *FOXD1* expression may lead to a defective premigratory-to-migratory transition occurring in CHARGE iPSC-NCCs. While delamination in vivo is not so simple as this in vitro model, as it is subject to complex orchestration by various signals, this delamination model may be a very valuable tool, since it is impractical for ethical and technical reasons to observe human NCC delamination in early embryos directly.

Second, our transwell migration assay using dissociated iPSC-NCCs, which occurred after delamination in vivo, showed defective CHARGE cell migration ([Figure 5](#fig5){ref-type="fig"}). As shown in [Figure 3D--E](#fig3){ref-type="fig"}, many genes referred to under the GO terms 'migration' and 'adhesion' were differentially expressed in CHARGE iPSC-NCCs, and the defective migratory phenotype of CHARGE iPSC-NCCs in the transwell assay is compatible with the results of this transcriptional analysis. This assay models cell migration toward chemoattractants. All cranial NCCs are suggested to have similar migratory potential, unlike trunk NCCs, which are known to be a heterozygous population consisting of cells such as leader cells and follower cells ([@bib45]). Therefore, this transwell migration assay is adequate for assessing the migration of cranial NCCs such as our iPSC-NCCs that robustly express OTX2 ([Figure 2H](#fig2){ref-type="fig"}). Of course, during the long journey from the dorsal neural tube to the ventral area, many signals influence NCC migration in a complex manner, and NCCs change their character during their migration. In our model, the in vivo migration provided additional evidence supporting the defective migration of CHARGE iPSC-NCCs.

Third, a spontaneous motility assay allowed us to assess whether defective motility is a partial cause of the defective migration of CHARGE iPSC-NCCs ([Figure 6](#fig6){ref-type="fig"}). In this assay with a mixed population of control and CHARGE iPSC-NCCs (co-culture system), autocrine or paracrine factors would likely diffuse within the wells and affect neighboring cells. The observed spontaneous defective motility of the CHARGE cells suggests that such soluble factors are not involved in the defective migration of CHARGE iPSC-NCCs.

Our transcriptome analysis revealed that genes associated with 'migration' and 'adhesion' were altered in CHARGE iPSC-NCCs. CHD7 is an important chromatin remodeler and may thus play roles in various gene regulatory mechanisms ([@bib6]) ([@bib19]) ([@bib23]) ([@bib35]; [@bib49]). In particular, we focus on the PAX6 downstream and Hippo/YAP pathways. Importantly, CHD7 is considered to function cooperatively with SOX2 as a molecular partner ([@bib16]), and PAX6 has also been reported to be a functional partner of SOX2 ([@bib55]). As shown in [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}, the expression levels of *POU3F2* (*BRN2*) and *OLFM3* (Optimedin) were significantly downregulated in CHARGE compared with control iPSC-NCCs, and these two genes have been reported to be targets of PAX6 ([@bib17]) ([@bib39]) ([@bib44]). POU3F2 is involved in controlling the migration of melanocytes, which are neural crest derivatives ([@bib8]). OLFM3 is considered to be involved in cell-cell adhesion and cell attachment to the extracellular matrix ([@bib17]). Several downstream targets of Pax6 have been identified as cell adhesion molecules and structural proteins ([@bib15]). Altered *CHD7* expression resulted in the upregulation of *PAX6* and the downregulation of PAX6 downstream genes ([Figure 3E](#fig3){ref-type="fig"}). Therefore, it is conceivable that CHD7 regulates multipotent NCC migration by cooperating with PAX6.

Next, *CTGF* and *EDN1*, known to be downstream factors in the Hippo-YAP signaling pathway, are highly expressed in CHARGE iPSC-NCCs compared with control cells ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The Hippo-YAP signaling pathway is known to be regulated via cell density ([@bib61]), and this pathway has recently been reported to inhibit migration and suggested to play important roles on the early stage of NCC specification and migration ([@bib27]; [@bib58]). In particular, CTGF and EDN1 play important roles in craniofacial development, and the timing and regulation of their expression are crucial for their function ([@bib32]; [@bib34]). Altered *CHD7* expression in iPSC-NCCs resulted in the upregulation of *CTGF* and *EDN1*. Therefore, it is conceivable that CHD7 regulates the craniofacial phenotype of CHARGE syndrome through the Hippo-YAP pathway. To clarify this mechanistic insight into how NCCs are dysregulated in CHARGE syndrome patients, it is noteworthy that 202 of the 338 differentially expressed genes between the CHARGE and control iPSC-NCCs were listed as target genes of CHD7 in the ChIP-seq datasets from the ENCODE Transcriptional Factor Target dataset ([@bib47]). Although these target sites vary depending on cell type, we found the target site of *CHD7* in the EDN1 distal promoter region by ChIP-qPCR for CHD7 using our cells. This result suggests that CHD7 regulates not only the expression of some specific key genes but also the robust gene expression in early NCCs.

The current study represents the first model of a developmental morphogenetic disorder using patient-derived iPSCs. To date, the neural crest pathophysiology observed in CHARGE syndrome has not been examined directly using patient-derived cells due to technical challenges and ethical concerns surrounding the collection of NCCs from human embryos. Moreover, since the developmental regulation of NCCs is known to be unique to individual species ([@bib1]; [@bib7]), NCCs derived from CHARGE patient-derived iPSCs are an appropriate source for modeling the cellular features of this disease in vitro.

We suggest that such cells may be used as a powerful assay system for evaluating NCC dysfunction in other morphogenetic disorders that could be considered neurocristopathies, such as craniofacial syndrome ([@bib37]) and infants of vitamin A exposure([@bib25]; [@bib46]). NCCs play important roles in the formation of sensory organs, such as ears, eyes, and olfactory organs, and some congenital neurocristopathies are caused by reproductive toxicity. These deformities of experimental animals have been used for the toxicity testing of newly developed drugs. The iPSC-NCC system presented herein could be used as an animal-free NCC system for reproductive toxicity testing.

Materials and methods {#s4}
=====================

Clinical description of the enrolled patients with CHARGE syndrome {#s4-1}
------------------------------------------------------------------

As shown in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}, patient1 (CH1), a Japanese male, was born at 39 weeks of gestation with a birth weight of 3.3 kg and a length of 50.5 cm. As major diagnostic criteria, he was noted to have external asymmetrical ear defects and bilateral sensorineural hearing loss (\>70 dB). A computed tomography (CT) scan of the temporal bones revealed that semicircular canals were bilaterally hypoplastic. He also showed velopharyngeal incoordination and gastroesophageal reflux. Development was severely delayed, with a developmental quotient of 15 at 3 years old. He had micropenis, cryptorchidism, and delayed incomplete pubertal development. His height was 126.0 cm (-- 2.1 s.D.), and his weight was 25.2 kg (-- 1.3 s.D.) at 10 years and 6 months old. He was noted to have a distinctive CHARGE physiognomy ([@bib10]). By the direct sequencing of his genomic DNA, a heterozygous nonsense mutation in *CHD7*, i.e., c.4171delC p.Gln1391fs\*13, was identified. Patient2 (CH2), a Japanese female, was born at 38 weeks of gestation with a birth weight of 3.03 kg and a length of 48.6 cm. She was noted to have external asymmetrical ear defects and bilateral sensorineural hearing loss (\>95 dB). A CT scan of the temporal bones revealed that semicircular canals were bilaterally hypoplastic, and the numbers of turns to the cochlea were decreased (Mondini defects). She also showed velopharyngeal incoordination and bilateral retinal coloboma with visual impairment. As minor diagnostic criteria ([@bib10]), development was severely delayed with a developmental quotient of 50 at 5 years old. She had delayed incomplete pubertal development. Her height was 119.5 cm (-- 2.7 s.D.), and her weight was 21.5 kg (-- 1.6 s.D.) at 10 years old. Her physiognomy showed features typical of CHARGE syndrome. By the direct sequencing of her genomic DNA, a heterozygous nonsense mutation in *CHD7*, i.e., c.4480C \> T p. Arg1493Ter, was identified.

Generation and maintenance of iPSCs from dermal fibroblast {#s4-2}
----------------------------------------------------------

As a control, WD39-iPSCs were derived from the HDFs of a healthy 16-year-old Japanese female ([@bib22]). 201B7-iPSCs and WA29-iPSCs were derived from the HDFs of a 36-year-old Caucasian female (Cell Applications Inc., San Diego, CA). 1210B2-iPSCs and 1201C1-iPSCs were derived from human peripheral blood mononuclear cells of a healthy 29-year-old African/American female (Cellular Technology Limited). 201B7-iPSCs, 1210B2-iPSCs, and 1201C1-iPSCs were kindly provided by Shinya Yamanaka. ([@bib41]; [@bib54]) KhES1-ESCs were kindly provided by Norio Nakatsuji ([@bib52]). CH1-iPSCs and CH2-iPSCs were derived from the HDFs of a 10-year-old Japanese male patient and the HDFs of a 10-year-old Japanese female patient, respectively. The clinical diagnoses of these two CHARGE syndrome patients were made based on the Blake criteria ([@bib10]). WD39-iPSCs, 201B7-iPSCs, WA29-iPSCs were established through the retroviral transduction of four transcription factors (*KLF4, OCT4, SOX2, and c-MYC*) into HDFs ([@bib54]), and 1210B2-iPSCs and 1201C1-iPSCs were established using the combination of *KLF4, OCT4, SOX2,L-MYC, LIN28, EBNA* and shRNA for *TP53,* as previously described ([@bib41]). The maintenance of HDFs, stem cell culture, characterization and teratoma formation were performed as described previously ([@bib21]; [@bib40]; [@bib54]). We performed mycoplasma contamination test using MycoAlert Mycoplasma Detection Kits (Lonza Walkersville, Inc., Walkersville, MD) and confirmed all lines were not contaminated by mycoplasma. All human cell and tissue donors were provided explanatory materials and a verbal explanation of the procedure, detailing both the procedure and the purposes of the experiment, as well as their rights, prior to collection and use. All experimental procedures were reviewed and approved by the Keio University School of Medicine Ethics committee (Approval Number: 20080016). RRIDs (Research Resource Identifiers) were provided as below; KhES1 (CVCL_B231), WD39 (CVCL_Y528), 201B7 (CVCL_A324), WA29 (CVCL_LJ40), 1210B2 (CVCL_LJ38), 1201C1 (CVCL_LJ37), CH1\#7 (CVCL_LJ32), CH1\#11 (CVCL_LJ31), CH1\#20 (CVCL_Y955), CK1\#25 (CVCL_Y956), CH2\#1 (CVCL_LJ\#33), CH2\#16 (CVCL_LJ\#34) and CH2\#19 (CVCL_LJ35).

Teratoma formation assay {#s4-3}
------------------------

To assess the pluripotency of generated iPSCs, we transplanted these iPSCs into the testis of 8-week-old NOD/SCID mice (OYG International) as previously described ([@bib40]). Eight weeks after transplantation, teratomas were dissected and fixed with 4% PFA in PBS. Paraffin-embedded tissue was sectioned and stained with hematoxylin and eosin. Images were obtained with a BZ-9000 (Keyence) microscope. All experimental procedures were reviewed and approved by the Keio University Institutional Animal Care and Use Committee (Approval Number: 09169).

Sequencing of *CHD7* mutation in enrolled patients {#s4-4}
--------------------------------------------------

The molecular tests for the *CHD7* gene mutations were conducted as previously reported ([@bib3]). We confirmed that the fibroblasts and iPSCs from both CHARGE syndrome patients showed mutations in *CHD7*, whereas the control fibroblasts and iPSCs did not, by sequencing of the PCR amplicons with the primers below using an automated sequencer ABI3100 (Thermo Fisher Scientific, Waltham, MA) as previously described. ([@bib3])

Primer sets:

*CHD7* exon17 F: CTATGCGTCAGGCCTCCTT

*CHD7* exon17 R: TGGGTCTGACTGGTACTCTCTG

*CHD7* exon19 F: TGCAGCATTTGTTTAGTCTGC

*CHD7* exon19 R: TTCCCAATGCATCTTGTAAGC 

qRT-PCR assay {#s4-5}
-------------

Total RNA was isolated and extracted as previously described. cDNA synthesis from RNA was performed using Superscript III reverse transcriptase (Thermo Fisher Scientific), followed by digestion with RNase H (Thermo Fisher Scientific). qRT-PCR was performed using a 7900HT Real-Time PCR system (Thermo Fisher Scientific) or a Viia7 Real-Time PCR system (Thermo Fisher Scientific) with SYBR green (TaKaRa, Kusatsu, Japan). For every set of qRT-PCR analyses, we had three technical replicates and at least three biological replicates. Data were analyzed by Dunn's multiple comparisons test after Kruskal-Wallis test using GraphPad Prism software version 7.0a (GraphPad Software). The following primers were used:

Primer sets:

*CTGF* F: CAAGGGCCTCTTCTGTGACT

*CTGF* R: ACGTGCACTGGTACTTGCAG

*EDN1* F: GACATCATTTGGGTCAACACTC

*EDN1* R: GGCATCTATTTTCACGGTCTGT

*OLFM3* F: CAGGAGGAAATTGGTGCCTA

*OLFM3* R: AGGGTCTGTCATCCAAGCAC

*POU3F2* F: CGGCGGATCAAACTGGGATTT

*POU3F2* R: TTGCGCTGCGATCTTGTCTAT

TaqMan Gene Expression Assays, Inventoried

*CHD7* primer: Assay ID: Hs00214990_m1

*GAPDH* primer: Assay ID: Hs99999905_m1

ChIP-qRT-PCR analysis for CHD7 {#s4-6}
------------------------------

Cells were crosslinked with 1% formaldehyde for 10 min, incubated with 200 mM glycine for 5 min and then stored at −80°C until use. The ChIP assay was performed as previously described ([@bib24]). Co-immunoprecipitated DNA was used as a template for PCR of the genomic region. The genomic regions were determined by the NCC-specific enhancer regions identified, as previously described ([@bib43]). Data were analyzed by paired t test using GraphPad Prism software version 7.0a (GraphPad Software). The following primers were used:

Primer sets:

h*POU3F2* distal enhancer F: CAGTAAGCTGCTTGGCCATT

h*POU3F2* distal enhancer R: CAGCCCTCCCTCCTCTTAAC

h*OLFM2* distal enhancer F: CAATCCCATCTGACCCAACT

h*OLFM2* distal enhancer R: CTGGCTGGTTTCCAGGTTTA

h*EDN1* distal enhancer F: TTCCCTCAGCTTTTGCTTGT

h*EDN1* distal enhancer R: ATTTGGGGGCTTTTTGAGAA

h*CTGF* distal enhancer F: GATTTCAGCTGCTGGCTACC

h*CTGF* distal enhancer R: ATGGCTATCACTTGCCTGCT

Flow cytometry {#s4-7}
--------------

Day 10 iPSC-NCCs obtained by Method B were detached with Accutase (Innovative Cell Technologies, San Diego, CA) and collected with ice-cold MACS buffer (Miltenyi Biotec, Bergisch Gladbach, Germany) consisting of phosphate-buffered saline (PBS), 0.5 M EDTA, and 5% bovine serum albumin. After washing, the cells were suspended in ice-cold MACS buffer at 2 × 10^5^ cells/ml and stained for 30 min at 4°C using PE-conjugated anti-human CD271 (NGFR) mouse IgG1 antibody (BioLegend, San Diego, CA) and FITC-conjugated anti-human CD57 (B3GAT) mouse IgM antibody (Beckman Coulter, Brea, CA). Propidium iodide staining allowed for the exclusion of dying/dead cells from the analysis. Isotype controls were used as negative controls. Flow cytometric analyses were performed using a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ).

Immunocytochemical analysis of iPSCs and NCCs {#s4-8}
---------------------------------------------

Cells were fixed with PBS containing 4% paraformaldehyde (PFA) for 15 min at room temperature. The cells were analyzed by immunofluorescence staining using the following antibodies: AP2α (monoclonal, 1:100; Cell Signaling Technologies, Danvers, MA), β-III tubulin (monoclonal, 1:1000; Sigma-Aldrich), CD90 (monoclonal, 1:100; BD Pharmingen, San Diego, CA), FOXG1 (polyclonal, 1:250; Abcam, Cambridge, UK), GFAP (monoclonal, 1:200; Thermo Fisher Scientific), Mash1 (monoclonal, 1:500; BD Pharmingen), OTX2 (polyclonal, 1:100; R and D Systems, Minneapolis, MN), P75NTR (polyclonal, 1:500; Abcam), SMA (monoclonal, 1:500; Sigma-Aldrich), SOX10 (polyclonal, 1:200; Abcam), Peripherin (polyclonal, 1:500; Merck Millipore, Billerica, MA), TRA-1--60 (monoclonal, 1:200; Millipore), and TRA-1--81 (monoclonal, 1:200; Merck Millipore). Immunoreactivity was visualized with secondary antibodies conjugated with Alexa 488, Alexa 568, or Alexa 647 (1:1000, Thermo Fisher Scientific). Nuclei were counterstained using Hoechst 33258 (10 μg/ml, Sigma-Aldrich). Images were obtained using an Apotome (Carl Zeiss, Oberkochen, Germany) or LSM-710 confocal (Carl Zeiss) microscope.

Generation of NCCs by method A {#s4-9}
------------------------------

The NCC differentiation of iPSCs was performed as previously described with some modifications ([@bib29]; [@bib30]). Briefly, dissociated iPSCs were plated onto an AggreWell 400 plate (Stem Cell Technologies, Vancouver, Canada) at a density of 600, 000 cells/ well in human ES medium consisting of DMEM/Ham's F12 (Sigma-Aldrich), 20% Knockout Serum Replacement (Thermo Fisher Scientific), 2 mM L-glutamine (Thermo Fisher Scientific), 1 × 10^−4^ M non essential amino acids (Sigma-Aldrich), 1 × 10^−4^ M 2-mercptoethanol (Sigma-Aldrich), and 0.5% penicillin and streptomycin (Thermo Fisher Scientific), the mediun also contained 10 μM Y-27632 (Wako Pure Chemical Industries, Osaka, Japan) in order to make homogenous embryoid bodies (EBs) consisting of 400 cells. After 40 hr, the EBs were transferred to a bacteria dish and cultured in suspension for a week in human EB medium consisting of DMEM/Ham's F12 (Sigma-Aldrich), 5% Knockout Serum Replacement (Thermo Fisher Scientific), 2 mM L-glutamine (Thermo Fisher Scientific), 1 × 10^−4^ M non-essential amino acids (Sigma-Aldrich), 1 × 10^−4^ M 2-mercaptoethanol (Sigma-Aldrich), 0.5% penicillin and streptomycin, and containing 10 μM SB431542 (R and D Systems), and 250 μg/ml Noggin-Fc (R and D systems). At day 8, the human EB medium was replaced with N2 medium consisting of DMEM/Ham's F12, GlutaMax-I (Thermo Fisher Scientific), 0.5% GlutaMax (Thermo Fisher Scientific), 1% N2 supplement (Thermo Fisher Scientific), 0.5% insulin (Thermo Fisher Scientific), 0.5% penicillin and streptomycin, and containing 10 μM SB431542 (Sigma-Aldrich), and 250 μg/ml Noggin-Fc (R and D Systems). At day 15, the EBs were replaced in a 6-well plate coated with 10 ng/ml fibronectin (Sigma-Aldrich) and cultured in N2 medium supplemented with 20 ng/ml of human recombinant EGF (PeproTech, Rocky Hill, NJ) and 20 ng/ml of human recombinant FGF2 (PeproTech). After 5--7 days of adhesion culture, the cells had migrated out from the colonies were collected and subjected to the analysis. The medium was changed every three days in this protocol.

Generation of NCCs by method B  {#s4-10}
-------------------------------

iPSCs were differentiated into NCCs, as previously described. ([@bib6]). Briefly, iPSCs were incubated with 2 mg/ml collagenase IV (Thermo Fisher Scientific). Once the iPSCs were detached, the clusters were broken into pieces consisting of 100--200 cells and plated onto a 100 mm petri dish (Becton Dickinson) in hNCC medium (NC medium). The medium consisted of 1:1 neurobasal medium (Thermo Fisher Scientific) and DMEM/F-12 medium containing 1x GlutaMax (Thermo Fisher Scientific), 5 mg/ml insulin (Sigma-Aldrich), 0.5% penicillin and streptomycin, 0.5x GEM 21 NeuroPlex serum-free supplement (Gemini Bio Products, West Sacramento, CA), 0.5x N2 supplement and supplemented with 20 μg/ml human recombinant EGF and 20 μg/ml human recombinant FGF2. The medium was changed every other day. After seven days of differentiation, migratory NCCs appeared from the attached spheres. At 3--4 days after their appearance, the cells were used for subsequent analysis.

Multipotency of iPSC-derived NCCs {#s4-11}
---------------------------------

We induced in vitro differentiation into adipocytes, chondrocytes, and osteocytes as previously reported ([@bib28]). Differentiated cells were stained by Toluidine blue (Wako Pure Chemical Industries), Safranin-O (Wako Pure Chemical Industries), and Alizarin red (Wako Pure Chemical Industries). We also differentiated them into myofibroblast (SMA+) and peripheral neurons (peripherin+) and performed an immunocytochemical analysis. In vivo differentiation of iPSC-NCCs into chondrocytes: We dissociated Method B iPSC-NCCs at day 10 with Accutase and purified the TRA-1--60-negative fraction using a MACS system (Miltenyi Biotec). We next injected 1.0 × 10^6^ TRA-1--60-negative cells into the testes of 8-week-old NOD-SCID mice, as previously described ([@bib40]). Eight weeks after transplantation, the testes were dissected and fixed with 4% PFA in PBS. The paraffin-embedded tissue was sectioned and stained with toluidine blue (performed by Dept. of Pathology, Keio University School of Medicine). Images were obtained using a BZ-9000 (Keyence, Osaka, Japan) microscope.

Expression array with iPSC-NCCs obtained by method B {#s4-12}
----------------------------------------------------

Total RNA was isolated from day-10 iPSC-NCCs using TRIzol (Thermo Fisher Scientific) according to the manufacturer's protocol and further purified with an RNeasy mini kit (Qiagen, Hilgen, Germany). Two replicates were run per line from two independent inductions. For the microarray analysis, RNA quality was assessed using a 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA). Total RNA (100 ng) was reverse-transcribed, biotin-labeled, and hybridized to a Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA), which was subsequently washed and stained in a Fluidics Station 450 according to the manufacturer's instructions ([@bib31]) ([@bib20]). The microarrays were scanned using a GeneChip Scanner 3000 7G (Affymetrix), and the RMA algorithm was implemented for the background correction, normalization across arrays, and log2 transformation of the raw image files ([@bib11]). Normalized data were filtered based on gene expression level and analyzed using GeneSpring GX software 14.5 (Agilent Technologies) for producing scatter plots and using R package (gplots) for producing heatmaps ([@bib59]). The GeneChip data were deposited in the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through the GEO series accession number GSE86212.

Dispersion assay with Delaunay triangulation {#s4-13}
--------------------------------------------

In this assay, we used iPSC-NCCs obtained by Method A. At day 15, EBs replated onto a fibronectin (10 ng/ml)-coated 8well-plastic-bottomed chamber (ASAHI GLASS, Tokyo, Japan) were imaged for 8 hr. To analyze how the cells dispersed from each sphere, the Delaunay triangulation algorithm was used ([@bib12]). ALl cells around the spheres were connected to their closest neighboring cells, and the network shaped triangles by this algorithm. This algorithm is available as an ImageJ plugin. Data were analyzed by Mann-Whitney U test using GraphPad Prism software version 7.0a (GraphPad Software).

Scattering assay {#s4-14}
----------------

In this assay, we used iPSC-NCCs obtained by Method A. On day 16, we attached a floating sphere onto the well of a 24-well plate coated with fibronectin (10 μg/ml) and cultured it in N2 medium supplemented with 20 ng/ml of human recombinant EGF and 20 ng/ml of human recombinant FGF2. After five days of adhesion culture, cells were fixed with PBS containing 4% PFA for 15 min at room temperature. F-actin and nuclei were stained using Alexa Fluor-488 phalloidin (Thermo Fisher Scientific) and Hoechst 33258 (Sigma-Aldrich), respectively. Images were obtained using a BZ-9000 (Keyence) microscope. To quantify intercellular contacts of iPSC-NCCs, we analyzed the outermost nine cells in each of the eight 45 degree-sector of a sphere by counting the number of their contacting-neighboring cells ([Figure 4F](#fig4){ref-type="fig"}), and we classified them into three groups, 0, 1, and \>1. Each cell line was analyzed in at least three independent experiments. Data were analyzed Dunnett's multiple comparisons tests after one-way ANOVA or Dunn's multiple comparison test after Kruskal-Walli test using GraphPad Prism software version 7.0a (GraphPad Software).

xCELLigence assay {#s4-15}
-----------------

We used Method B NCCs for this assay. We dissociated day-10 iPSC-NCCs into single cells with Accutase (Innovative Cell Technologies Inc.). We used the xCELLigence-DP system (Roche) with CIM-Plate 16 to measure the migration index of each type of iPSC-NCCs. The upper plate of CIM-Plate 16 was coated with fibronectin (10 μg/ml in PBS), and 100,000 cells were added to each upper well. NC medium without human recombinant EGF and human recombinant FGF2 was added into each upper well, and NC medium without human recombinant EGF and human recombinant FGF2 containing 10% fetal bovine serum was added to each lower well. Cells that migrated from the upper to the lower well were automatically measured by the xCELLigence system. Eventually, aphidicolin (Sigma, Saint Louis, MO) was used at the concentration of 10 μg/ml. Data were analyzed by Tukey\'s multiple comparisons test after one-way ANOVA and Sidak's multiple comparisons test after two-way repeated measure ANOVA using GraphPad Prism software version 7.0a (GraphPad Software).

BrdU incorporation in vitro {#s4-16}
---------------------------

Passaged day10 iPSC-NCCs were seeded into wells of an 8-well glass-bottomed plate coated with poly-L-ornithine (0.1 mg/ml) and fibronectin (10 μg/ml) at a low density in NC medium supplemented with 10 μM BrdU (Sigma-Aldrich). After 24 hr, the cells were fixed with PBS containing 4% PFA for 15 min at room temperature and immunostained with sheep polyclonal anti-BrdU antibody (1:500; Fitzgerald Industries International, Acton, MA). Images were randomly captured with an Apotome microscope, and the cells were manually counted. Data were analyzed by unpaired t test using GraphPad Prism software version 7.0a (GraphPad Software).

Cell adhesion assay {#s4-17}
-------------------

Control iPSC-NCCs and CHARGE iPSC-NCCs obtained by Method B were used for this assay. Each iPSC-NCCs type was cultured to semi-confluence in NC medium, detached by 5 min of treatment with Accutase, and were washed with NC medium twice. We resuspended the cells at a density of 1 × 10^5^ cells per ml in NC medium, and added 100 μl of cell suspension to each well of a fibronectin-coated 96-well plate. After 60 min incubation at 37°C, we changed the medium and added 10 μl of WTS-1/ECS (MerckMillipore, Billerica, USA) per well except for 12 wells per 96-well plate. After 90 min of incubation at 37°C, the plate was shaken thoroughly for 1 min on a shaker, and then the absorbance at 450 nm of the treated and untreated samples was measured using a microplate reader. The average of absorbance values of the 12 wells without WTS-1/ECS was considered a baseline, and the data were normalized to that of 201B7 iPSC-NCCs in each experiment. Data were analyzed by Dunnett\'s multiple comparisons test after one-way repeated measures ANOVA using GraphPad Prism software version 7.0a (GraphPad Software). ([@bib13]) ([@bib38]).

Spontaneous single cell motility assay {#s4-18}
--------------------------------------

Control iPSC-NCCs and CHARGE iPSC-NCCs obtained by Method B were used for this assay. At day 10--12, after the beginning of differentiation by Method B, the remaining spheres were removed by direct aspiration with a fine Pasteur pipette. The adherent NCCs were washed 2--3 times gently with PBS, and then stained for 3 hr at 37°C with either Vybrant DiI (Thermo Fisher Scientific) or Vybrant DiO (Thermo Fisher Scientific) diluted 1/300 in NC medium. Notably, permutations of the staining dyes confirmed that the nature of the dye had no effect on the migratory behavior of the cells. After 4--5 washes with PBS, the stained NCCs were then dissociated using Accutase, counted using Trypan Blue (Wako Pure Chemical Industries), and then co-seeded in equal amounts at a density of 5 × 10^3^ cells/well (total of 10 × 10^3^ cells per well) onto 8-well, plastic-bottomed chambers that were previously coated with fibronectin at 10 μg/ml. Three hours after seeding, once the cells had attached, the chambers were transferred to an LSM 5, PASCAL Exciter confocal microscope (Carl Zeiss) that was equipped with a heat- (37°C) and gas-controlled incubation chamber (5% CO~2~) (Tokai Hit, Shizuoka, Japan) that was coupled to a heated motorized stage. The objective lens (EC-Plan Neofluar, 10 X, Numerical Aperture 0.3) was maintained at 37°C and was used to acquire a Z-stack time-lapse series (7 Z-stacks spanning 30 μm, every 15 min) of multiple locations. Z-projections were produced using Image Browser Zeiss software at the end of the analysis. The time-lapse recordings began at 4 hr after seeding and continued for at least 16 hr. Individual cells were manually tracked using the Manual Tracking plugin of the Fiji software (1.48). Cells exhibiting abnormal morphologies (e.g., neurite-like, or with signs of apoptosis) were excluded from the analysis. Calculations of individual velocities and directionalities were performed using the chemotaxis and migration tool from Ibidi (Martinsried, Germany). Data were analyzed Sidak's multiple comparisons tests after two-way repeated measures ANOVA using GraphPad Prism software version 7.0a (GraphPad Software).

In ovo experiments {#s4-19}
------------------

Control and CHARGE floating spheres at day seven were stained with Vybrant DiI and Vybrant DiO respectively for 6 hr each and were seeded into the same 100 mm Petri dish to make mixture of dual colored NCCs sheet. On day 10 dual-colored NCCs were dissected with a needle as a cluster and transplanted into the dorsal side (top) of the developing neural tube at the hindbrain level of HH stage 8--10 chick embryos. The embryos were incubated for 36 hr, and imaged with an SVZ16 (Olympus, Tokyo, Japan) stereo microscope.

Time-lapse imaging of transplanted cells during in ovo experiments {#s4-20}
------------------------------------------------------------------

We transplanted control and CHARGE iPSC-NCCs into chick embryos, as described above. At 6 hr after transplantation, we started to perform time-lapse imaging as previously described ([@bib53]). Briefly, transplanted chick embryos were placed on a Millicell-CM membrane (pore size, 0.4 μm; Millipore) and cultured in saline, which is described below. The dishes were then mounted onto a confocal microscope (FV1000, Olympus Optical). Approximately, 20 optical Z-section images were acquired at an interval of 5 μm every 15 min, and all focal planes (100 μm) were merged. Individual cells were manually tracked using the Manual Tracking plugin of the Fiji software (1.48). Data were analyzed by two-way repeated measures ANOVA using GraphPad Prism software version 7.0a (GraphPad Software).

The saline used consisted of the following: solution A (for 1 l): 121.0 g of NaCl, 15.5 g of KCl, 10.4 g of CaCl~2~.2H~2~O, and 12.7 g of MgCl~2~.6H~2~O; solution B (for 1 l): 2.4 g of Na~2~HPO~4~.2H~2~O and 0.2 g of NaH~2~PO~4~.2H~2~O. After autoclaving but prior to using the solutions, mix 120 ml of solution A with 2700 ml of H~2~O; then, add 180 ml of solution B, as previously described ([@bib42]).
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Decision letter

Bronner
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Reviewing Editor
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United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The reviewers have decided to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a well-conducted and relevant study modeling the CHARGE syndrome with induced pluripotent stem cells. The results suggest for the first time an exciting functional phenotype of neural crest cells from CHARGE patients. They observed a migratory deficit consistent with the patient phenotype making this study a very promising line of work. The reviewers agree that this study is potentially interesting and appropriate for *eLife*. However, the paper needs additional analyses to study cell migration as well as better controls and numbers to guarantee significance.

Essential revisions:

1\) The characterization of the migratory/dispersion phenotype shown in [Figure 4](#fig4){ref-type="fig"} is not convincing. The image quality in [Figure 4](#fig4){ref-type="fig"} is inadequate. The authors only show a movie of control cells, but none of CHARGE cells which would be needed to evaluate the CHARGE phenotype.

2\) Analysis of dispersion needs to be improved. The ratio of cell number with non-attached neighboring cells is not appropriate for quantification as it depends on the number of cells analyzed, the perimeter of the cell cluster, etc. Distance to the closer neighbor expressed as a ratio between t0 and tn, using Delaunay triangulation would be a better measure. They should also analyze other parameters like cell speed, persistence, cell area, time of contact etc.

3\) The trans-well assay employed to study cell motility is not ideal, as it is prone to several artifacts (e.g. differential adhesion, differential proliferation, etc.). Time-lapse imaging of individually migrating cells is the most direct assay for cell motility. This analysis is shown in [Figure 6](#fig6){ref-type="fig"}. But why is there a continuous increase in cell velocity? This is an important observation that needs to be investigated further. Cell velocity is a cell property that can be affected by external stimulus of by cellular activities; therefore if the external and internal conditions of a cell are stable, the velocity should be constant. If the conditions are changing, it won\'t be possible to compare two cell populations (control and CHARGE cells).

4\) The transplantation experiments to study cell migrating in vivo are interesting, but the analysis is not adequately performed. Time lapse movies and analysis of cell motility in vivo should be performed.

5\) The authors show one control and two CHARGE syndrome iPSC lines but these are not isogenic. Can they rule out possible allelic variations? To address this, the authors should either increase the numbers of control and CHARGE lines to a minimum of 3 lines each to be statistically conclusive or prepare an isogenic control.

6\) The global gene expression studies are convincing and provide some discussion on possible involvement of altered genes and pathways. However no further verification/ confirmation has been made. This would greatly enhance this paper.

7\) To corroborate the migratory phenotype, they should include further analysis of intracellular filaments/focal adhesion/integrin machinery to suggest molecular culprits of the migratory phenotype.

10.7554/eLife.21114.034

Author response

> Essential revisions:
>
> 1\) The characterization of the migratory/dispersion phenotype shown in [Figure 4](#fig4){ref-type="fig"} is not convincing. The image quality in [Figure 4](#fig4){ref-type="fig"} is inadequate. The authors only show a movie of control cells, but none of CHARGE cells which would be needed to evaluate the CHARGE phenotype.

Per the suggestion of the comment, we replaced the image of the

migratory/dispersion phenotype to better represent the iPSCs-NCCs in [Figure 4](#fig4){ref-type="fig"} ([Figures 4A-a, 4A-b](#fig4){ref-type="fig"}, and 4E). We have added a movie of CHARGE cells in [Figure 4---video 2](#fig4video2){ref-type="video"}, in addition to a movie of control cells in [Figure 4---video 1](#fig4video1){ref-type="video"}.

> 2\) Analysis of dispersion needs to be improved. The ratio of cell number with non-attached neighboring cells is not appropriate for quantification as it depends on the number of cells analyzed, the perimeter of the cell cluster, etc. Distance to the closer neighbor expressed as a ratio between t0 and tn, using Delaunay triangulation would be a better measure. They should also analyze other parameters like cell speed, persistence, cell area, time of contact etc.

a\) Analysis of dispersion using Delaunay triangulation

Per the suggestion of the reviewer comment, we analyzed the dispersion of migrating cells from a sphere using the Delaunay triangulation algorithm, and we could easily recognize the difference between the control and CHARGE cells using the algorithm. The statistical analysis of increased triangle area between t=0 and t=8h in the control and CHARGE cells revealed a delayed dispersion of cells in CHARGE-spheres. We have added the results of the assay to [Figures 4B, 4C](#fig4){ref-type="fig"}, and 4D. We have added the following sentences to the Results section of the revised manuscript to explain the additional dispersion assay using a Delaunay triangulation:

"...neighbors ([Figure 4A-b](#fig4){ref-type="fig"}). To clarify this difference, we performed a time-lapse analysis of the initial phase of cell dispersion from the sphere. \[...\] Moreover, to determine whether CHARGE iPSC-NCCs have defects in premigratory-to-migratory transition, we analyzed the intercellular contacts of both control and CHARGE iPSC-NCCs at Phase 2. We visualized..."

b\) Analysis of cell speed, persistence, cell area, time of contact.

We apologize for not showing a video of CHARGE cells in our previous submission. Without the video, it is difficult to understand how CHARGE cells migrate out from a sphere. As shown in [Figure 4---video 1](#fig4video1){ref-type="video"} and [2](#fig4video2){ref-type="video"}, at first, cells began to spread out as a continuous monolayer (Phase 1); then, cells at the outermost periphery began to disperse (Phase 2). During Phase 1, cell speed seemed to be dependent on the spreading speed of each sphere, which was especially clear for CHARGE cells. The spreading speed was quite different from sphere to sphere. As such, it was difficult to analyze the spreading speed in this assay. Instead, in the analysis shown in [Figure 6](#fig6){ref-type="fig"} of the time-lapse imaging of individually migrating cells, control and CHARGE cells were observed under the same condition, and by measuring the velocity of each cell type, we found defective motility in CHARGE iPSC-NCCs in the present revised manuscript.

Regarding cell persistence, or directionality, cells just moved to the outside of a sphere along with sphere spreading during Phase 1, so directionality was also along the direction of sphere spreading. During Phase 2, as cells at the outermost periphery began to migrate apart, it was a good phase for measuring directionality. However, when CHARGE cells started to migrate away from the spheres, the migrating cells began to leave the observation field. In the analysis shown in [Figure 6](#fig6){ref-type="fig"} of the time-lapse imaging of individually migrating control and CHARGE cells under the same condition (in co-culture), we measured the directionality of the cells and found no difference between the control and CHARGE iPSC-NCCs.

Regarding the time of contact, in the beginning of this assay, cells contacted

> each other because they were all from a sphere. In this assay, we focused on observing how cells spread out from a sphere and began to disperse. When they started to migrate apart from each other (Phase 2), especially for CHARGE cells, many cells left the observation field. Along with the analysis of the scattering assay, shown in [Figures 4E and 4F](#fig4){ref-type="fig"}, we could reveal significant persistent intercellular contacts among CHARGE iPSC-NCCs compared with control iPSC-NCCs.
>
> 3\) The trans-well assay employed to study cell motility is not ideal, as it is prone to several artifacts (e.g. differential adhesion, differential proliferation, etc.). Time-lapse imaging of individually migrating cells is the most direct assay for cell motility. This analysis is shown in [Figure 6](#fig6){ref-type="fig"}. But why is there a continuous increase in cell velocity? This is an important observation that needs to be investigated further. Cell velocity is a cell property that can be affected by external stimulus of by cellular activities; therefore if the external and internal conditions of a cell are stable, the velocity should be constant. If the conditions are changing, it won\'t be possible to compare two cell populations (control and CHARGE cells).

1\) The artifacts of differential adhesion and differential proliferation in the transwell assay.

Per the suggestion of the reviewer comment, we performed adhesion and proliferation assays to determine whether there was a difference between control and CHARGE iPSC-NCCs grown onto fibronectin (the extracellular matrix protein we used in the transwell assay).

Regarding the effect of differential adhesion, we performed a cell adhesion assay to fibronectin and then found no significant difference between the control and CHARGE iPSC-NCCs ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Regarding the effect of differential proliferation, we first noted that use of the anti-mitotic drug aphidicolin, an inhibitor of DNA replication, did not significantly affect the migration rate of NCCs in transwell assay, indicating that proliferation is not significantly contributing to the increased impedance over time, as shown in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. We also performed a BrdU incorporation assay with control and CHARGE iPSC-NCCs, and no significant difference was observed, also shown in [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}. By these assays, we could conclude that the reduction in the number of migrating CHARGE iPSC-NCCs observed in the transwell assay was not due to reduced proliferation and lower CHARGE iPSC-NCC adherence to fibronectin.

We consider that the transwell assay with the xCELLigence system is a good tool for monitoring the continuous kinetic record of cell migration and quantifying the defective migration in CHARGE iPSC-NCCs objectively. These results are also supported by the defective cell motility of CHARGE iPSC-NCCs revealed by the single-cell motility analysis, as shown in [Figure 6B](#fig6){ref-type="fig"}. We have added the following sentences to the Results section of the present revised manuscript:

"...cells ([Figure 5C](#fig5){ref-type="fig"}). To exclude the possibility that the reduction in the number of migrating CHARGE iPSC-NCCs was due to reduced proliferation, we treated control iPSC-NCCs with an antimitotic, aphidicolin. \[...\] Taken together, these results suggest that CHARGE iPSC-NCCs exhibit aberrant migration, in contrast with their preserved capacity for proliferation and adherence to fibronectin."

2\) A continuous increase in cell velocity in the time-lapse imaging of individually migrating cells.

As mentioned by the reviewer comment, we have observed a continuous increase in cell velocity in both control and CHARGE iPSC-NCCs. We are not sure what causes the continuous increase in cell velocity, but the phenomenon has been observed in multiple independent experiments. This effect (progressive increase of velocity over time) has not been reported in the literature regarding neural crest cells. Recently it was reported that a continuous increase in cell velocity of metastatic human sarcoma and carcinoma cells was observed in vitro as the cell density increases (Jayatilaka et al., 2017). Even though we didn\'t observe such cell density increase during the assay, there is some possibility that autocrine/paracrine signaling may cause a continuous increase in cell velocity. Although the reason is unknown, it should be emphasized that the control and CHARGE iPSC-NCCs were recorded while in co-culture so that they encountered the same condition. We explicitly stated that the velocity increased over time, and have added the following sentences to the Results and Discussion sections of the present revised manuscript:

"...iPSC-NCCs. To exclude cell-density effects, we analyzed the motility of mixed iPSC-NCCs, i.e., control + CHARGE, within the same well ([Figure 6.A](#fig6){ref-type="fig"}). The tracking of individual iPSC-NCCs revealed that the average velocities progressively increased over the course of the recording period ([Figure 6B](#fig6){ref-type="fig"}).

Notably,.."

"Third, a spontaneous motility assay allowed us to assess whether defective motility is a partial cause of the defective migration of CHARGE iPSC-NCCs ([Figure 6](#fig6){ref-type="fig"}). \[...\] The observed spontaneous defective motility of the CHARGE cells suggests that such soluble factors are not involved in the defective migration of CHARGE iPSC-NCCs."

\* Jayatilaka, H., Tyle, P., Chen, J. J., Kwak, M., Ju, J., Kim, H. J.,. . . Wirtz, D. (2017). Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nat Commun, 8, 15584. doi:10.1038/ncomms15584

> 4\) The transplantation experiments to study cell migrating in vivo are interesting, but the analysis is not adequately performed. Time lapse movies and analysis of cell motility in vivo should be performed.

Per the suggestion of the reviewer comments, we have added a representative time-lapse movie as an illustration of the defective migration of CHARGE iPSC-NCCs transplanted in ovo as shown in [Figure 7---video 1](#fig7video1){ref-type="video"}, and a quantitative analysis of the data as shown in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.

We have repeatedly performed transplantation of a mixture of control and CHARGE iPSC-NCCs into a chick embryo, but only few embryos were survived. Besides, due to the movements of the developing chick embryos, capturing and tracking the implanted cells over a significant period of time after the initial phase were revealed to be extremely difficult. Therefore, we limited the observation time-window to the first 6 hours after transplanted cells started to migrate. We provided a representative time-lapse movie as an illustration of the defective migration of CHARGE iPSC-NCCs transplanted in ovo compared with control cells. We manually tracked individual migratory control and CHARGE cells in an embryo over time using ImageJ, and revealed significant reduced cell velocity in CHARGE in ovo using total nine embryos by two-way ANOVA (time, and cell type). Along with the analysis of cell motility in vivo with time-lapse movies, we think that our scoring system shown in [Figure 7](#fig7){ref-type="fig"} reflects faithfully the biological events: while the control NCCs exhibited superior behavior compared with the CHARGE NCCs in some embryos, there were also some embryos where both cell types behaved similarly. Whether this variability is a reflection of the extent of a malformation observed in CHARGE patients is unknown.

We have added a representative time-lapse video to [Figure 7---video 1](#fig7video1){ref-type="video"}, the following images to [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, and the following sentences to the Results section of the revised manuscript:

"...transplantation ([Figure 7A](#fig7){ref-type="fig"}).First, to examine the serial migration of the transplanted cells, we transferred the transplanted embryo to a glass-bottomed plate (IWAKI) 6 h after transplantation and then acquired time-lapse images every 20 min ([Figure 7---video 1](#fig7video1){ref-type="video"}). \[...\] ([Figure 7---figure supplement 1---source data 1](#fig7s1sdata1){ref-type="supplementary-material"}, Tab1) Collectively, CHARGE iPSC-NCCs exhibited a lower velocity compared with that of the co-transplanted control iPSC-NCCs (P = 0.03; Wilcoxon signed-rank test) ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Second,.."

> 5\) The authors show one control and two CHARGE syndrome iPSC lines but these are not isogenic. Can they rule out possible allelic variations? To address this, the authors should either increase the numbers of control and CHARGE lines to a minimum of 3 lines each to be statistically conclusive or prepare an isogenic control.

Per the suggestion of the comment, we added several lines to the control and CHARGE groups to meet the minimum of 3 lines per group for obtaining statistically conclusive evidence of the defective migration of CHARGE iPSC-NCCs. To perform the following functional migration assay, as shown in [Figures 4D, 4F](#fig4){ref-type="fig"}, [5C](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and 7, we had to prepare both control and CHARGE iPSC-NCCs at the same time. Sometimes we failed to induce a sufficient number of iPSC-NCCs to analyze, so we always maintained several iPSC lines and differentiated NCCs from them. As such, the line \# combinations are not the same for each migration analysis. However, we obtained similar results from each cell line combination, and we think that these results accurately reflect the biological events. We have revised [Figures 1E](#fig1){ref-type="fig"}, [4F](#fig4){ref-type="fig"}, and 5C to reflect the line numbers in each group and have also made a new figure or a new source data to be representative of the number of each line in the assay, as shown in [Figures 4D](#fig4){ref-type="fig"}, [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}---source data 1.

[Figure 1E](#fig1){ref-type="fig"}: We used 3 lines (WD39, 201B7, 1210B2) as control cells and 36 lines (CH1\#1, CH1\#3-CH1\#21, CH1\#24, CH1\#25, CH2\#1-CH2\#3, CH2\#5, CH2\#7, CH2\#8, CH2\#10, CH2\#16-CH2\#23) as CHARGE cells.

[Figure 4D](#fig4){ref-type="fig"} (Dispersion assay): We used 3 lines (WD39, 201B7, 1201C1) as control cells and 3 lines (CH1\#20, CH1\#25, CH2\#1) as CHARGE cells.

[Figure 4F](#fig4){ref-type="fig"} (Scattering assay): We used 4 lines (KhES1, WA29, 201B7, WD39) as control cells and 5 lines (CH1\#20, CH1\#25, CH2\#1, CH2\#16, CH2\#19) as CHARGE cells.

[Figure 5C](#fig5){ref-type="fig"} (transwell migration assay): We used 3 lines (WD39, 201B7, 1210B2) as control cells, 3 lines (CH1\#7, CH1\#20, CH1\#25) from CH1, and 3 lines (CH2\#1, CH2\#16, CH2\#19) from CH2.

[Figure 6](#fig6){ref-type="fig"} (spontaneous motility assay): We used 2 lines (WD39, 201B7) as control cells and 2 lines (CH1\#25, CH2\#16) as CHARGE cells. In this assay, to maintain the control and CHARGE iPSC-NCCs under identical conditions, we compared recordings of co-cultured control and CHARGE iPSC-NCCs. Thus, the statistical analysis was also performed using 1 control line and 1 CHARGE line in each experiment. The defective motility of the CHARGE iPSC-NCCS observed in this assay is compatible with the results from the transwell migration assay, as shown in [Figure 5C](#fig5){ref-type="fig"}. The transwell migration assay was performed with 4 control lines and 5 CHARGE lines.

[Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}---source data 1 (in vivo migration assay): We used 3 control lines (WD39, 201B7, 1201C1) and 3 CHARGE lines (CH1\#25, CH2\#1, CH2\#16). As with [Figure 6](#fig6){ref-type="fig"}, we compared control and CHARGE iPSC-NCCs co-transplanted in an embryo to maintain the control and CHARGE iPSC-NCCs under identical conditions. Thus, the statistical analysis was also performed using 1 control line and 1 CHARGE line in each experiment.

> 6\) The global gene expression studies are convincing and provide some discussion on possible involvement of altered genes and pathways. However no further verification/ confirmation has been made. This would greatly enhance this paper.

Per the suggestion of the comment, we additionally performed ChIP-qPCR for *CHD7* with control iPSC-NCCs to examine whether the potential targets identified in our study are directly regulated by CHD7 binding. The genomic regions were determined by the NCC-specific enhancer regions identified using the same NCC differentiation method we used in this paper (Method B), as previously described (Rada-Iglesias et al., 2012). As shown in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, we found direct CHD7 binding to the distal enhancer sites of *EDN1*. We have added the following sentences to the Results section and Discussion section of the revised manuscript:

"...the analysis ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These genes are also listed as CHD7 targets in the dataset. \[...\] The results of these transcriptome analyses support the notion that NCCs exhibit migratory and/or cell adhesion defects during embryonic development in CHARGE patients."

"...dataset (Rouillard et al., 2016). Although these target sites vary depending on cell type, we found the target site of CHD7 in the EDN1 distal promoter region by ChIP-qPCR for CHD7 using our cells. This result suggests that CHD7 regulates not only the expression of some specific key genes but also the robust gene expression in early NCCs."

> 7\) To corroborate the migratory phenotype, they should include further analysis of intracellular filaments/focal adhesion/integrin machinery to suggest molecular culprits of the migratory phenotype.

Per the suggestion of the comment, we have performed immunostaining for key regulators of cell shape and dynamics: β-actin, F-actin (stained by phalloidin), and α- tubulin. However, we couldn't see any difference between control and CHARGE iPSC-NCCs regarding either the intensity of immunoreactivities, or the patterns of staining (see [Author response image 1](#respfig1){ref-type="fig"}). It thus seems necessary to perform specific assays to reveal subtle differences between control and CHARGE-NCCs regarding the mechanism involved in the defective migration of CHARGE-NCCs.

![](elife-21114-resp-fig1){#respfig1}

In line with this idea, we have thereafter examined the cell surface expression of integrins alpha4 and beta1, which are especially relevant to interactions with fibronectin. FACS analysis has revealed a tendency to a reduction in surface intensities of both integrins alpha4 and beta1 (see [Author response image 2](#respfig2){ref-type="fig"}). Strachan et al. have shown that these proteins are particularly important for the migration of cranial NCCs onto fibronectin (Strachan and Condic, 2003). However, consistent data from the literature suggests that the possibly reduced expression of these integrins would positively affect the velocities of NCCs migration at the relatively high concentrations of fibronectin (10 µg/ml) used in our migration assays (transwell and spontaneous single cell motility). On the contrary, CHARGE iPSC-NCCs exhibited reduced migration capabilities compared to control iPSC-NCCs in these conditions, indicating that the modulation of surface integrin expression is not likely to be involved in the defective migration of CHARGE NCCs.

According to such a situation, we did not include these results in the manuscript.

![The results of flow cytometric analysis of control and CHARGE iPSC-NCCs from method-B (control; red line, CHARGE; blue line).\
Isotype controls were used as negative controls (black line).](elife-21114-resp-fig2){#respfig2}

While the differences of immunolocalization of these molecules are not obvious, we could detect that the expression levels of various genes involved in cell adhesion and migration are changed in CHARGE cells by transcriptome analysis ([Figure 3D, E](#fig3){ref-type="fig"}). Thus, expression of these molecules is likely to be orchestrated by CHD7 and would result in the remarkable phenotypes in CHARGE cells in our model.

\* Strachan, L. R., & Condic, M. L. (2003). Neural crest motility and integrin regulation are distinct in cranial and trunk populations. Developmental Biology, 259(2), 288-302.[@bib2]
